


JDRF Facts

About JDRF

JDRF is the only global organization with a strategic research plan to end type 1 diabetes (T1D). Our plan ensures that there will be an ongoing stream of life-changing therapies moving from development through to the marketplace that lessen the impact of T1D. We want to keep people with T1D healthy and safe today until we reach our ultimate goal of a cure and universal prevention of T1D, and turn Type One into Type None.

JDRF collaborates with a wide spectrum of partners at every stage of the drug delivery pipeline and is the only organization with the scientific resources, regulatory influence, and a strategic plan to deliver a world without T1D. JDRF's influence and leadership extends beyond funding research. We strategically partner with industry, governments, foundations, academia, and clinicians, because curing T1D is a global, coordinated effort with JDRF at the center.



Research Facts and Figures

- Currently, JDRF is supporting \$568 million in active T1D research projects worldwide.
- In 2013 alone, JDRF's T1D research funding totaled more than \$106 million.
- JDRF currently has research projects taking place in 17 countries throughout the globe.
- JDRF's 2013 research funding included \$78 million in U.S.-based projects, and \$28 million in international projects.
- Since its founding in 1970, JDRF's cumulative research funding totals over \$1.8 billion.
- JDRF is currently funding more than 50 human clinical trials.

Research Plan

JDRF research focuses on key therapies that hold significant promise in turning Type One into Type None:

Artificial Pancreas: a series of increasingly sophisticated artificial pancreas systems that progressively eliminate blood glucose testing and automate delivery of insulin and additional hormones

Complications: therapies that progressively treat and reverse debilitating complications resulting from the impact of T1D throughout the body


Encapsulation: implantable beta cell replacement therapies that restore insulin independence without the need for intensive immune suppression

Prevention: slow or halt the progression of T1D before insulin dependence, and long-term, eliminate the risk of developing the disease

Restoration: the body's beta cell function is restored and the autoimmune attack is haltedin short, the biologic cure for T1D

Smart Insulin: single dose of insulin that circulates in the bloodstream and turns on when it's needed and off when it's not

Research Funding Breakdown



^{*} Includes \$13 million supporting the long-term goal of restoring insulin production and curing T1D, and \$3 million supporting near-term goals of better treating T1D.

About T1D

Type 1 diabetes (T1D) is an autoimmune disease in which a person's pancreas stops producing insulin, a hormone people need to get energy from food. T1D strikes both children and adults, and lasts a lifetime. T1D has nothing to do with diet or lifestyle, and there is nothing you can do to prevent it.

Just to survive, people with T1D must frequently test their blood sugar and inject insulin (or continually infuse it through a pump) every day. They must carefully balance insulin doses with eating and other daily activities—and still run the risk of dangerous high or low blood sugar levels. Taking insulin does not cure T1D, nor does it prevent the possibility of the disease's devastating effects: kidney failure, blindness, nerve damage, heart attack, stroke, and pregnancy complications.

T1D Facts and Figures

T1D impacts millions of lives throughout the world.

30,000

The number of people diagnosed with T1D every year in the US

\$14 billion The annual US costs of T1D

The number of those living with T1D who are adults

The increase in the prevalence of T1D in 23% people under age 20 from 2001 to 2009

26 million The total number of Americans with all types of diabetes